[ad_1] This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia…
Tag: Cybin
Cybin Announces up to US$64 Million Offering of Units
[ad_1] This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia…
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit
[ad_1] This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia…
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines | BioSpace
[ad_1] – With the recently announced definitive agreement to acquire Small Pharma Inc. The granted patent will add to the most impressive intellectual property portfolio in the psychedelic drug development…
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines
[ad_1] This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia…
Cybin to Acquire Small Pharma Inc. | BioSpace
[ad_1] – All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics – – Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and…
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program | BioSpace
[ad_1] – Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 – – Company’s intellectual property portfolio now…
Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights
[ad_1] – Initiated First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial – – Topline clinical data readouts expected in Q3/Q4 2023, including Phase 2a efficacy data for CYB003 and…